Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

BACKGROUND: The adoptive transfer of tumor-infiltrating lymphocytes (TIL) has demonstrated robust efficacy in metastatic melanoma patients. Tumor antigen–loaded dendritic cells (DCs) are believed to optimally activate antigen-specific T lymphocytes. We hypothesized that the combined transfer of TIL,...

Descripción completa

Detalles Bibliográficos
Autores principales: Saberian, Chantal, Amaria, Rodabe N., Najjar, Amer M., Radvanyi, Laszlo G., Haymaker, Cara L., Forget, Marie-Andrée, Bassett, Roland L., Faria, Silvana C., Glitza, Isabella C., Alvarez, Enrique, Parshottam, Sapna, Prieto, Victor, Lizée, Gregory, Wong, Michael K., McQuade, Jennifer L., Diab, Adi, Yee, Cassian, Tawbi, Hussein A., Patel, Sapna, Shpall, Elizabeth J., Davies, Michael A., Hwu, Patrick, Bernatchez, Chantale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144048/
https://www.ncbi.nlm.nih.gov/pubmed/34021033
http://dx.doi.org/10.1136/jitc-2021-002449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144048/
https://www.ncbi.nlm.nih.gov/pubmed/34021033
http://dx.doi.org/10.1136/jitc-2021-002449

Ejemplares similares